导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.15% | 2152/4773 |
| 近一周 | -2.04% | 1112/5462 |
| 近一月 | -3.98% | 2124/5421 |
| 近一季 | -6.77% | 2189/5209 |
| 近半年 | -2.04% | 1758/4920 |
| 近一年 | 2.82% | 2045/4366 |
| 近两年 | 52.69% | 1403/2954 |
| 近三年 | 32.81% | 942/2253 |
| 成立以来 | 60.97% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.07% 3022/4961 |
13.87% 1925/5312 |
- - |
- - |
| 2025 | 21.61% 2023/4813 |
-0.70% 2367/3635 |
2.05% 1914/4076 |
19.10% 2186/4524 |
0.76% 1787/4813 |
| 2024 | 16.55% 795/3463 |
2.64% 738/2808 |
-1.39% 1058/3014 |
16.53% 1429/3129 |
-1.18% 1614/3463 |
| 2023 | -9.96% 1251/2656 |
3.88% 1100/2280 |
-4.89% 1317/2385 |
-2.99% 818/2515 |
-6.06% 1617/2655 |
| 2022 | -18.12% 665/2207 |
-14.39% 940/1919 |
7.81% 425/2016 |
-12.54% 725/2113 |
1.43% 1269/2208 |
| 2021 | 4.38% 583/1822 |
-2.76% 699/1255 |
8.54% 614/1330 |
-3.12% 615/1466 |
2.09% 703/1822 |
| 2020 | - - |
- - |
17.25% 380/1067 |
15.49% 211/1164 |
12.91% 416/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 招商MSCI中国A股国际通ETF VS. 长安沪深300非周期A(740101) |